TytoCare

Remote Primary Care and a Home Smart Clinic

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in June 2012 by Dedi Gilad and Ofer Tzadik, TytoCare operates with 201–500 employees. The company has raised over $228.6 million across 9 funding rounds from 20 investors, with Insight Partners being a notable lead investor. In July 2026, TytoCare appointed Adam Pellegrini as CEO and closed a growth round to scale its AI-first clinical enablement platform.

Business overview

TytoCare is a virtual healthcare company that provides remote primary care through its Home Smart Clinic. The company's core technology combines an FDA-cleared device with AI-powered guidance and diagnostic support, enabling families to conduct remote physical exams and receive immediate answers from doctors. TytoCare serves over 220 major health systems and health plans globally, operating within the Health Tech & Life Sciences sector, with a focus on digital healthcare and medical devices.

Strategic signal

In July 2025, TytoCare announced a restructuring effort, including workforce optimization and a strategic shift to focus on the US market and the development of FDA-approved AI diagnostics. This move signals the company's commitment to advancing its AI capabilities and streamlining operations to address the growing shortage of family physicians, indicating a strategic pivot towards specialized, AI-driven diagnostic solutions within the telehealth market.

Company Intelligence Q&A

What was the most recent leadership change at TytoCare?
In July 2026, TytoCare appointed Adam Pellegrini as its new CEO. Co-founder Dedi Gilad transitioned from day-to-day management to focus on long-term strategy.
What was TytoCare's most recent funding activity?
In July 2026, TytoCare closed a growth round of over $25 million to scale its AI-first clinical enablement platform. Insight Partners led this round, with participation from Qumra Capital.
What strategic shift did TytoCare announce in July 2025?
In July 2025, TytoCare announced a restructuring that included workforce optimization and a strategic focus on the US market and the advancement of FDA-approved AI diagnostics. This aims to address the increasing shortage of family physicians.
What recent recognition did TytoCare receive for its AI technology?
In October 2025, TIME recognized TytoCare's AI Respiratory Suite among its Best Inventions of 2025, highlighting the company's leadership in AI-powered diagnostic solutions.
What recent FDA clearance did TytoCare receive for its AI capabilities?
In July 2024, TytoCare received FDA clearance for its AI Lung Crackle Detection technology, further enhancing its diagnostic accuracy from home.

External links